至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo

Life Sci. 2020; 
Xuemei Ji, Tianzhen Han, Nannan Kang, Song Huang, Yu Liu
Products/Services Used Details Operation
Recombinant Antibody Expression … The cDNA coding for the VHH was amplified from the recombinant VHH pMD18-T vector by polymerase chain reaction (PCR), and the RGD4C sequence and primers were synthesised in Genscript Corporation (Nanjing, China) … Get A Quote

摘要

objective: Triple-negative breast cancer (TNBC) is not sensitive to current endocrine treatments, so new treatment strategies need to be explored. Based on previous antitumour studies on anti-TNFα nanobody, we designed a novel fusion nanobody to enhance antitumour activity of the anti-TNFα nanobody in TNBC. methods: The RGD4C contains RGD sequence, which is the smallest recognition unit binding to the αvβ3 receptor on tumour cell membranes and involved in tumour cell adhesion, proliferation, and metastasis. RGD4C was fused to anti-TNFα nanobody to investigate the antitumour activity in vitro and in vivo. results: The antitumour effects of fusion nanobody V-L-R-H could effectively bind to αvβ3 and inhibit... More

关键词

Epithelial-mesenchymal transition, Fusion nanobody, RGD4C, TNFα, Triple-negative breast cancer, αvβ3